Inflammatory and non-inflammatory roles for toll-like receptors in gastrointestinal cancer

Research output: Contribution to journalArticleResearchpeer-review

8 Citations (Scopus)

Abstract

Collectively, cancers of the gastrointestinal (GI) tract (including the esophagus, stomach, duodenum, colon, rectum, liver, gall bladder and bile ducts) are the most prevalent and deadly worldwide. A common denominator in the pathogenesis of these GI tract cancers is chronic inflammation, as evidenced by the fact that sufferers of inflammatory bowel disease (IBD) are significantly more susceptible to colon cancer than healthy individuals. However, since only a relatively small proportion of individuals with chronic inflammatory conditions such as IBD go on to develop cancer, research has focused on identifying discrepancies in the host immune system that may be responsible for promoting carcinogenesis in inflamed tissue. To this end, molecular pathways linking inflammation and cancer are emerging, with one series of candidates being members of the Toll-like receptor family
Original languageEnglish
Pages (from-to)2968 - 2977
Number of pages10
JournalCurrent Pharmaceutical Design
Volume21
Issue number21
Publication statusPublished - 2015

Cite this

@article{5ff8f0a49a6f422b9b895e3ebd88340c,
title = "Inflammatory and non-inflammatory roles for toll-like receptors in gastrointestinal cancer",
abstract = "Collectively, cancers of the gastrointestinal (GI) tract (including the esophagus, stomach, duodenum, colon, rectum, liver, gall bladder and bile ducts) are the most prevalent and deadly worldwide. A common denominator in the pathogenesis of these GI tract cancers is chronic inflammation, as evidenced by the fact that sufferers of inflammatory bowel disease (IBD) are significantly more susceptible to colon cancer than healthy individuals. However, since only a relatively small proportion of individuals with chronic inflammatory conditions such as IBD go on to develop cancer, research has focused on identifying discrepancies in the host immune system that may be responsible for promoting carcinogenesis in inflamed tissue. To this end, molecular pathways linking inflammation and cancer are emerging, with one series of candidates being members of the Toll-like receptor family",
author = "West, {Alison C} and Jenkins, {Brendan John}",
year = "2015",
language = "English",
volume = "21",
pages = "2968 -- 2977",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers",
number = "21",

}

Inflammatory and non-inflammatory roles for toll-like receptors in gastrointestinal cancer. / West, Alison C; Jenkins, Brendan John.

In: Current Pharmaceutical Design, Vol. 21, No. 21, 2015, p. 2968 - 2977.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Inflammatory and non-inflammatory roles for toll-like receptors in gastrointestinal cancer

AU - West, Alison C

AU - Jenkins, Brendan John

PY - 2015

Y1 - 2015

N2 - Collectively, cancers of the gastrointestinal (GI) tract (including the esophagus, stomach, duodenum, colon, rectum, liver, gall bladder and bile ducts) are the most prevalent and deadly worldwide. A common denominator in the pathogenesis of these GI tract cancers is chronic inflammation, as evidenced by the fact that sufferers of inflammatory bowel disease (IBD) are significantly more susceptible to colon cancer than healthy individuals. However, since only a relatively small proportion of individuals with chronic inflammatory conditions such as IBD go on to develop cancer, research has focused on identifying discrepancies in the host immune system that may be responsible for promoting carcinogenesis in inflamed tissue. To this end, molecular pathways linking inflammation and cancer are emerging, with one series of candidates being members of the Toll-like receptor family

AB - Collectively, cancers of the gastrointestinal (GI) tract (including the esophagus, stomach, duodenum, colon, rectum, liver, gall bladder and bile ducts) are the most prevalent and deadly worldwide. A common denominator in the pathogenesis of these GI tract cancers is chronic inflammation, as evidenced by the fact that sufferers of inflammatory bowel disease (IBD) are significantly more susceptible to colon cancer than healthy individuals. However, since only a relatively small proportion of individuals with chronic inflammatory conditions such as IBD go on to develop cancer, research has focused on identifying discrepancies in the host immune system that may be responsible for promoting carcinogenesis in inflamed tissue. To this end, molecular pathways linking inflammation and cancer are emerging, with one series of candidates being members of the Toll-like receptor family

UR - http://www.eurekaselect.com/131277/article

M3 - Article

VL - 21

SP - 2968

EP - 2977

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 21

ER -